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ABSTRACT
Objectives: To assess the effect of vitamin A
supplementation in women of reproductive age in
Ghana on cause- and age-speciﬁc infant mortality. In
addition, because of recently published studies from
Guinea Bissau, effects on infant mortality by sex and
season were assessed.
Design: Double-blind, cluster-randomised, placebo-
controlled trial.
Setting: 7 contiguous districts in the Brong Ahafo
region of Ghana.
Participants: All women of reproductive age
(15e45 years) resident in the study area randomised
by cluster of residence. All live born infants from 1
June 2003 to 30 September 2008 followed up through
4-weekly home visits.
Intervention: Weekly low-dose (25 000 IU) vitamin A.
Main outcome measures: Early infant mortality
(1e5 months); late infant mortality (6e11 months);
infection-speciﬁc infant mortality (0e11 months).
Results: 1086 clusters, 62 662 live births, 52574
infant-years and 3268 deaths yielded HRs (95% CIs)
comparing weekly vitamin A with placebo: 1.04 (0.88
to 1.05) early infant mortality; 0.99 (0.84 to 1.18) late
infant mortality; 1.03 (0.92 to 1.16) infection-speciﬁc
infant mortality. There was no evidence of modiﬁcation
of the effect of vitamin A supplementation on infant
mortality by sex (Wald statistic ¼0.07, p¼0.80) or
season (Wald statistic ¼0.03, p¼0.86).
Conclusions: This is the largest analysis of cause of
infant deaths from Africa to date. Weekly vitamin A
supplementation in women of reproductive age has no
beneﬁcial or deleterious effect on the causes of infant
death to age 6 or 12 months in rural Ghana.
Trial registration number: http://ClinicalTrials.gov:
NCT00211341.
INTRODUCTION
Vitamin A deﬁciency is a major public
health problem. It is most prevalent in
young children and pregnant women in low-
income countries, especially in Africa and
South-East Asia.
1 Clinical vitamin A deﬁ-
ciency can manifest as xerophthalmia,
blindness and enhanced susceptibility to
infections especially measles.
2
Vitamin A supplementation in children
aged 6e59 months substantially reduces
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ARTICLE SUMMARY
Article focus
- This paper reports the results of planned
(a priori) analyses of the effect of vitamin A
supplementation in women of reproductive age
on cause- and age-speciﬁc infant mortality in the
ObaapaVitA trial.
- In addition, because of the recent interest in
potential differential effects, we also assessed
effects by sex and season.
Key messages
- The analyses from this trial indicate that weekly
vitamin A supplementation in women of repro-
ductive age has no beneﬁcial or deleterious effect
on the causes of death in their babies of age 6 or
12 months, no effect on infection-speciﬁc infant
mortality and no role for inclusion in child
survival programs in Asia and Africa.
- We also failed to demonstrate any beneﬁt or
harm from vitamin A supplementation in women
of reproductive age and in infant males or
females in our study population. There was
also no modiﬁcation of the effect of vitamin A
supplementation and mortality by season.
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3 4; these effects are apparent for deaths due to
diarrhoea and measles but not respiratory infections or
malaria.
35However, the effect of vitamin A supple-
mentation in children younger than 6 months is less
clear. Trials of supplementation of 25000 international
units (IU) vitamin A linked to each of the ﬁrst three
doses of diphtheriaetetanusepertussis immunisations
demonstrated no signiﬁcant effects on early or late
infant mortality.
6 Early studies from Guinea Bissau
suggested that there may be interaction with the season
of birth with higher mortality occurring in the rainy
season in neonates who were supplemented with vitamin
A.
78Findings from two trials in Guinea Bissau also
suggested increased mortality among girls, but not
among boys, in the second half of infancy following
neonatal vitamin A supplementation.
79However,
a recent meta-analysis involving all trials to date indi-
cated that there is no differential effect of neonatal
vitamin A supplementation in boys and girls.
10
A recent Cochrane review reported that vitamin A
supplementation in women of reproductive age has no
signiﬁcant effect on maternal or infant outcomes.
11 This
review included our recently reported ﬁndings from the
Ghana ObaapaVitA cluster-randomised trial of the
impact of weekly low-dose (25000 IU) vitamin A
supplementation given to women of reproductive age,
which suggested no beneﬁcial effect on the survival
of their babies.
12 However, there have been no reports of
the effect of vitamin A supplementation in women of
reproductive age on cause-speciﬁc infant mortality or on
mortality in early and late infancy. These outcomes were
not included in our initial publication due to space
limitations.
This paper reports the results of planned (a priori)
analyses of the effect of vitamin A supplementation in
women of reproductive age on cause- and age-speciﬁc
infant mortality in the ObaapaVitA trial. We hypoth-
esised that vitamin A supplementation would have
signiﬁcant effects on all three groups (neonatal, early
infant and late infant mortality). In addition, because of
the recent interest in potential differential effects, we
also assessed effects by sex and season.
METHODS
Methods are reported in detail elsewhere,
12 and the
full protocol is available online (at http://www.lshtm.
ac.uk/eph/nphir/research/obaapavita/obaapavita_trial_
protocol.pdf). In brief, all women aged 15e45 years living
in seven, predominantly rural, districts in the Brong
Ahafo region of Ghana, who were able to give informed
consent and who planned to live in the trial area for at
least 3 months were eligible for enrolment. Enrolment
started in December 2000 and continued throughout the
trial; ﬁeldworkers recruited eligible women who migrated
into their areas and girls who became ﬁfteen. The trial
ended in September 2008, with data collection
continuing through October 2008. Verbal postmortems
(VPMs) to ascertain cause of death were implemented for
all infant deaths from June 2003. Analyses in this paper
are therefore based on all live births that took place to
study participants between June 2003 and September
2008.
There are two distinct seasons in the study area.
OctobereMarch is the dry season with high tempera-
tures (mean 308C) and low rainfall (mean 100 mm).
AprileSeptember is the rainy season with lower
temperatures (mean 268C) and high rainfall (mean
1270 mm).
13
Intervention
Women were randomised, according to their cluster of
residence, to receive either weekly vitamin capsules,
containing 25000 IU (7500 mg) of vitamin A in soybean
oil in a dark red opaque soft gel, or identical-looking
placebo capsules containing only soybean oil. The
vitamin A dose was selected to deliver the recommended
dietary allowance while being safe during pregnancy.
14 15
The capsules were manufactured by Accucaps Industries
Limited, Windsor, Ontario, Canada; the vitamin A was
donated by Roche. Women were visited at home every
4 weeks, and given four capsules to be taken over the
next 4 weeks. Adherence was supported by an extensive
Information, Education and Communication
programme, based on formative research conducted
before the trial began.
16
Randomisation and blinding
The trial area was divided into clusters of compounds,
with ﬁeldworkers responsible for a ﬁeldwork area (FWA)
of four contiguous clusters, visiting women in one cluster
per week over a 4-weekly cycle. There were a total of 272
FWAs and 1086 clusters. Randomisation was by cluster
with two clusters in each FWA allocated to vitamin A and
two to placebo to ensure geographic matching of
vitamin A and control groups. A computer-generated
ARTICLE SUMMARY
Strengths and limitations of this study
- There were some limitations to our trial. There was no direct
observation of capsule taking; however, adherence was
supported by an extensive Information, Education and
Communication strategy, and we estimated that on average
75% of women both received and took all four capsules every
month.
- We also used verbal postmortems (VPMs) and physician
coders to assign cause of death, and it was not possible to use
health facility records or postmortem examinations to verify
the cause of death. Misclassiﬁcation is common in VPM
studies, but this can be minimised when broad categories such
as ‘infection’, ‘prematurity’ and ‘asphyxia’ are used. Our VPM
tools were also validated in similar study populations, and
acceptable sensitivity and speciﬁcity were reported in compar-
ison to a gold standard.
- Strengths included the fact that our study was large (62000
infants) prospective and population-based. All resident women
in the trial districts and their babies were enrolled, and loss to
follow-up was low, even in women with babies who had died.
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facturers by an independent statistician. The capsules
were packaged in labelled jars, for each cluster for each
week of the trial. No trial personnel (participants, care-
providers, data collectors, data analysts, investigators)
had access to the randomisation list or to any informa-
tion that would allow them to deduce or change the
cluster allocation.
Data collection
Fieldworkers collected data during 4-weekly home
visits on pregnancies, births, deaths, migrations, socio-
demographic characteristics of pregnant women and
number of capsules taken since the last visit. From June
2003, ﬁeld supervisors conducted VPMs with close rela-
tives or friends for all deaths reported among infants
born to trial women; these included an open history,
plus questions on signs, symptoms and the illness that
lead to death. Standard WHO VPM tools and methods
were used.
17 The methods have been presented and
validated in earlier papers.
18e20 VPMs were reviewed by
two experienced doctors, who independently assigned
a single primary cause of death using identical tools. If
the coders disagreed, the form was independently
reviewed by a third doctor and a consensus coding
accepted if two of the three agreed. If there was no
consensus, the three coders met to determine whether
they could reach agreement. The cause of death classi-
ﬁcation system had six major categories: congenital
abnormalities, prematurity, birth asphyxia, infection
(subdivided into neonatal, diarrhoea, pneumonia,
malaria, measles, other), other speciﬁc cause of death
and unexplained cause of death.
Sample size
Sample size for the trial was determined by the rarest
outcome, pregnancy-related mortality, to allow for the
detection of a reduction of 33% in pregnancy-related
mortality in the vitamin A arm, with 90% power and at
5% signiﬁcance, and allowing for a 10% design effect.
The sample size of 62000 infants was also sufﬁcient to
detect at least a 15% effect of vitamin A supplementation
on neonatal, early infant and late infant mortality.
Statistical methods
Stata V.10.0 was used for all analyses. Infant mortality
(deaths from 0 to 11 months of age), early infant
mortality (deaths from 1 to 5 months of age) and late
infant mortality (deaths from 6 to 11 months of age)
were all expressed per 1000 infant-years of follow-up.
Neonatal mortality (<1 month) was expressed per 1000
live births. Intention-to-treat analyses compared treat-
ment groups using logistic regression for neonatal
mortality and Cox regression for infant mortality.
Random-effects regression (for logistic regression) or
robust standard errors (for Cox regression) were used to
Figure 1 Proﬁle of trial and
subjects included in analysis of all
live births from 1 June 2003 to 30
September 2008.
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hazards assumption for all Cox regressions was assessed
using visual inspection of the NelsoneAalen log cumu-
lative hazard curves. Interaction between vitamin A
supplementation and season or gender was examined
using the likelihood ratio test (when using logistic
regression) or the Wald test (when using Cox regression).
Intention to treat was by cluster of residence. As
previously described,
12 we accounted for the fact that
vitamin A stores require some time to become replete or
depleted by excluding the ﬁrst 6 months of follow-up
after recruitment or after any change of treatment group
for the same reasons, and regarding women as
belonging to their pre-move group for a period of
2 months after changing group. Infants were considered
as belonging to the treatment arm of the mother at the
time of delivery.
Trial monitoring and ethical approval
The conduct of the trial was overseen by Trial Steering
and Data Monitoring and Ethics Committees. It was
approved by the ethics committees of the Ghana Health
Service and the London School of Hygiene and Tropical
Medicine and registered with http://clinicaltrials.gov
(identiﬁer NCT00211341). Full informed consent was
obtained from all trial participants.
RESULTS
Participant ﬂow
The trial proﬁle is shown in ﬁgure 1. One thousand and
eighty-six clusters (542 placebo, 544 vitamin A) in 272
FWAs were randomised. Recruitment, withdrawals and
migration patterns were similar in the vitamin A and
placebo arms, as were socio-demographic characteristics
(table 1). There were a total of 62662 live births to
50422 women of reproductive age in the trial from 1
June 2003 to 30 September 2008 with 52574 infant-years
of follow-up and 3268 infant deaths (ﬁgure 1). For
babies born before 31 October 2007, follow-up to 1 year
was 86%. Data collection for the trial ended on 31
October 2008, and 90% of the babies born after 31
October 2007 were seen in the last month of data
collection or had died before then.
Age at death
Overall, 58.9% (1925/3268) of the deaths occurred in
the neonatal period, 21.3% (699/3268) occurred in
early infancy (1e5 months) and 19.7% (644/3268)
occurred in late infancy (6e11 months) (table 2).
Mortality was comparable for the vitamin A and placebo
groups during the neonatal period and in early and late
infancy (table 3).
Cause of death
A suitable respondent was found for the administration of
3129 VPMs out of the total 3268 deaths (95.7%). Coders
were able to assign a cause for 2589 of these deaths
(82.7%). Causes of death were markedly different in the
neonatal (table 4) and postneonatal periods (1e11
months) (table 5). Asphyxia was coded as the most
common cause of neonatal death (37.0%; 568/1536),
followed by infection (28.8%; 442/1536) and prematurity
(18.3%; 281/1536). In contrast, infection was coded as
the cause of 94.2% (992/1053) of the postneonatal
deaths; 30% (298/992) of these infection deaths were due
to pneumonia, 22.9% (228/992) to malaria, 14.1% (140/
992) to diarrhoea, 0.6% (6/992) to measles and 32.3%
(320/992) were due to other infection (meningitis,
tetanus, HIV/AIDS or infection with an unknown cause).
The distributions of both neonatal and postneonatal
causes of death were similar in the placebo and vitamin
A groups (tables 4 and 5). There was no marked impact
Table 1 Comparability of vitamin A and placebo groups,
all live births from 1 June 2003 to 30 September 2008
Characteristic
Placebo,
n (%*)
Vitamin A,
n (%*)
Live births in study
population (n)
31164 (100) 31498 (100)
Age group at the birth outcome, years
<20 2404 (8) 2536 (8)
20e24 7645 (25) 7747 (25)
25e29 8866 (28) 8993 (29)
30e34 6848 (22) 6818 (22)
35e39 3784 (12) 3752 (12)
$40 1617 (5) 1652 (5)
Previous live births (n)
0 3463 (11) 3628 (12)
1 6032 (19) 6061 (19)
2 5812 (19) 5719 (18)
3 4628 (15) 4888 (15)
4 3664 (12) 3714 (12)
5+ 7217 (23) 7179 (23)
Not known 348 (1) 309 (1)
Highest educational level
None 12142 (39) 12280 (39)
Primary school 5812 (19) 5865 (19)
Secondary school 12515 (40) 12636 (40)
Technical college
or university
262 (1) 281 (1)
Not known 433 (1) 436 (1)
Religion
Christian 20663 (66) 20721 (66)
Muslim 7428 (24) 7594 (24)
Traditional African 1718 (6) 1803 (6)
Other 939 (3) 961 (3)
Not known 416 (1) 419 (1)
Ethnic group
Akan 13361 (43) 13693 (43)
Other 17392 (56) 17386 (55)
Missing 411 (1) 419 (1)
Wealth quintiles
1st (poorest) 8039 (26) 8339 (26)
2nd 6743 (22) 6666 (21)
3rd 5668 (18) 5768 (18)
4th 5177 (17) 5171 (16)
5th (richest) 4618 (15) 4670 (15)
Not known 919 (3) 884 (3)
*Percentages may not add up to 100 due to rounding.
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Vitamin A and infant mortalityof vitamin A supplementation on any speciﬁc cause of
mortality, either in the neonatal period (table 4)o ri n
the postneonatal period (table 5). The overall HR for
infection-speciﬁc infant mortality was 1.03 (95% CI 0.92
to 1.16).
Sex
Mortality rates were considerably lower for females
than males during the neonatal period and late infancy
(table 2). Mortality was also lower in females than males
in the early infant period, but this difference was
marginal and non-signiﬁcant. Mortality rates were
similar for the vitamin A and placebo groups for both
males and females in the neonatal period and early and
late infancy. There was also no evidence of modiﬁcation
of the effect of vitamin A supplementation on infant
mortality by sex (Wald statistic ¼0.07, p¼0.80).
Season
There was no obvious seasonality in mortality rates
(ﬁgure 2). Fifty-three per cent (1729/3268) of infant
deaths occurred in the rainy season (AprileSeptember)
and 47% (1539/3268) in the dry season (Octobere
March). Mortality rates were similar in both (HR 0.99
(95% CI 0.92 to 1.06), p¼0.67), and there was no impact
of vitamin A supplementation on infant deaths in either
the rainy (HR 0.98 (95% CI 0.89 to 1.08), p¼0.68) or the
dry season (HR 0.97 (95% CI 0.87 to 1.08), p¼0.56).
There was also no evidence of modiﬁcation of the effect
of vitamin A supplementation on infant mortality by
season (Wald statistic ¼0.03, p¼0.86).
DISCUSSION
This large-scale community-based trial provides the
largest analysis of cause of infant deaths from Africa to
date. Our analyses indicate that weekly vitamin A
supplementation in women of reproductive age has
no beneﬁcial or deleterious effect on the causes of
d e a t hi nt h e i rb a b i e so fa g e6o r1 2m o n t h si nr u r a l
Ghana.
We identiﬁed no other published studies of the effect
of vitamin A supplementation in women of reproductive
age on cause-speciﬁc infant mortality. In particular, no
cause-speciﬁc data have been reported from the other
two trials of maternal vitamin A supplementation in
Nepal
21 and Bangladesh.
22 23 Studies of maternal
multiple micronutrient supplementation have also not
reported effects on cause-speciﬁc infant mortality.
24 25
The biological action of vitamin A and previous evidence
from childhood vitamin A trials
52 6led us to postulate
a priori that vitamin A may have an effect on deaths due
to infant infection. However, we found no effect of
vitamin A on deaths due to infant infections in our study
population. It was also possible that vitamin A could have
had an effect on deaths due to prematurity-related
complications (eg, bronchopulmonary dysplasia,
necrotising enterocolitis, intraventricular haemorrhage)
as vitamin A has effects on epithelial integrity, cellular
differentiation and foetal surfactant synthesis.
22 7
However, we found no impact of vitamin A supplemen-
tation in women of reproductive age on prematurity-
speciﬁc neonatal mortality.
Table 2 Mortality by age and sex for infants born from 1 June 2003 to 30 September 2008
Overall Males* Females*
Neonatal deaths
Live births (n) 62662 31631 30980
Total neonatal deaths 1925 1113 790
Total neonatal deaths/1000
live births
30.72 35.19 25.50
OR (95% CI) e 1.00 0.72 (0.65 to 0.79)
p Value ee <0.0001
Infant deaths 1e5 months
Infant years of follow-up
1e5 months
23660 11886 11772
Total 1e5 months deaths 699 362 334
Total 1e5 months deaths/
1000 infant-years
29.54 30.46 28.37
HR (95% CI) e 1.00 0.93 (0.80 to 1.08)
p Value ee 0.35
Infant deaths 6e11 months
Infant years of follow-up
6e11 months
24094 12087 12005
Total 6e11 months deaths 644 352 292
Total 6e11 months deaths/
1000 infant-years
26.73 29.12 24.32
HR (95% CI) e 1.00 0.84 (0.72 to 0.98)
p Value ee 0.02
*Sex of baby unknown in 51 of 62662 infants.
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Vitamin A and infant mortalityThe absence of an impact on early or late infant
survival concurs with the ﬁndings of trials of maternal
vitamin A supplementation from Nepal
21 and
Bangladesh
22 23 and a pooled meta-analysis of the effects
of maternal multiple micronutrient supplements.
24 25
The results also concur with those of our main paper,
which reported no effects of vitamin A supplementation
in women of reproductive age on maternal mortality and
Table 4 Effect of weekly vitamin A supplementation on neonatal deaths by cause of death; intention-to-treat analyses, all live
births from 1 June 2003 to 30 September 2008
Placebo Vitamin A
All live births (n) 31164 31498
Total neonatal deaths 984 941
Infection
Infection-speciﬁc deaths (n) 218 224
Infection-speciﬁc deaths/1000 live births 7.00 7.11
Adjusted OR* (95% CI) 1.00 1.02 (0.84 to 1.23)
p Value e 0.86
Prematurity
Prematurity-speciﬁc deaths (n) 149 132
Prematurity-speciﬁc deaths/1000 live births 4.78 4.19
Adjusted OR* (95% CI) 1.00 0.88 (0.68 to 1.14)
p Value e 0.33
Asphyxia
Asphyxia-speciﬁc deaths (n) 284 284
Asphyxia-speciﬁc deaths/1000 live births 9.11 9.02
Adjusted OR* (95% CI) 1.00 0.99 (0.83 to 1.19)
p Value e 0.95
Other deathsy
Other deaths (n) 128 117
Other speciﬁc deaths/1000 live births 4.11 3.71
Adjusted OR* (95% CI) 1.00 0.89 (0.69 to 1.17)
p Value e 0.41
Unexplained
Unexplained deaths (n) 175 156
Unexplained deaths/1000 live births 5.62 4.95
Adjusted OR* (95% CI) 1.00 0.88 (0.71 to 1.10)
p Value e 0.26
Cause of death not ascertained
Unascertained deaths (n) 30 28
Unascertained deaths/1000 live births 0.96 0.89
Adjusted OR* (95% CI) 1.00 0.92 (0.55 to 1.55)
p Value e 0.76
*Adjusted for clustering by ObaapaVitA cluster of residence.
yIncludes congenital abnormality, accident or injury, malignant tumours and neonatal jaundice.
Figure 2 Births and infant
mortality per 1000 person-years,
by calendar month.
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Vitamin A and infant mortalitystillbirths.
12 However, none of these trials presented data
separately for males and females. We recorded lower
mortality rates in females than males throughout infancy
and markedly so during the neonatal period and late
infancy. We found no evidence of any differential effect
of vitamin A supplementation in boys or girls, or by
season. This is in contrast to the recent Guinea Bissau
trials which indicated that there may be an interaction
between neonatal vitamin A supplementation and
childhood immunisations by age, sex and season.
79
There were some limitations to our trial. There was no
direct observation of capsule taking; however, adherence
Table 5 Effect of weekly vitamin A supplementation on postneonatal deaths by cause of death; intention-to-treat analyses, all
live births from 1 June 2003 to 30 September 2008
Placebo Vitamin A
Infant-years of follow-up 23800 24097
Total postneonatal deaths 662 681
Infection
Infection-speciﬁc deaths (n) 479 503
Infection-speciﬁc deaths/1000 child-years 20.13 20.87
Adjusted HR* (95% CI) 1.00 1.04 (0.90 to 1.19)
p Value e 0.61
Pneumonia
Pneumonia-speciﬁc deaths (n) 152 146
Pneumonia-speciﬁc deaths/1000 child-years 6.39 6.06
Adjusted HR* (95% CI) 1.00 0.95 (0.75 to 1.21)
p Value e 0.67
Malaria
Malaria-speciﬁc deaths (n) 115 113
Malaria-speciﬁc deaths/1000 child-years 4.83 4.69
Adjusted HR* (95% CI) 1.00 0.97 (0.74 to 1.27)
p Value e 0.83
Diarrhoea
Diarrhoea-speciﬁc deaths (n) 60 70
Diarrhoea-speciﬁc deaths/1000 child-years 2.52 2.90
Adjusted HR* (95% CI) 1.00 1.15 (0.82 to 1.62)
p Value e 0.42
Measles
Measles-speciﬁc deaths (n) 4 2
Measles-speciﬁc deaths/1000 child-years 0.17 0.08
Adjusted HR* (95% CI) 1.00 0.49 (0.09 to 2.69)
p Value e 0.41
Other infectiony
Other infection deaths (n) 148 172
Other infection-speciﬁc deaths/1000 child-years 6.22 7.14
Adjusted HR* (95% CI) 1.00 1.15 (0.91 to 1.45)
p Value e 0.24
Other deathsz
Other deaths (n) 42 29
Other deaths/1000 child-years 1.76 1.20
Adjusted HR* (95% CI) 1.00 0.68 (0.42 to 1.10)
p Value e 0.12
Unexplained
Unexplained deaths (n) 106 103
Unexplained deaths/1000 child years 4.45 4.27
Adjusted HR* (95% CI) 1.00 0.96 (0.72 to 1.27)
p Value e 0.78
Cause of death not ascertained
Unascertained deaths (n) 35 46
Unascertained deaths/1000 child years 1.47 1.91
Adjusted HR* (95% CI) 1.00 1.30 (0.84 to 2.00)
p Value e 0.24
*Adjusted for clustering by ObaapaVitA cluster of residence.
yIncludes meningitis, tetanus, HIV/AIDS or infection with an unknown cause.
zIncludes congenital abnormality, accident or injury and malignant tumours.
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Vitamin A and infant mortalitywas supported by an extensive Information, Education
and Communication strategy, and we estimated that on
average 75% of women both received and took all four
capsules every month.
12 We also used VPMs and physi-
cian coders to assign cause of death, and it was not
possible to use health facility records or postmortem
examinations to verify the cause of death. Misclassiﬁca-
tion is common in VPM studies, but this can be mini-
mised when broad categories such as ‘infection’,
‘prematurity’ and ‘asphyxia’ are used.
17 19 Our VPM
tools were also validated in similar study populations,
and acceptable sensitivity and speciﬁcity were reported
in comparison to a gold standard.
17 18 20 In addition, our
study was prospective and population based. All resident
women in the trial districts and their babies were
enrolled, and loss to follow-up was low, even in women
with babies who had died.
Our ﬁndings have important implications for policy
and program development. They indicate that vitamin A
supplementation in women of reproductive age will not
reduce infection-speciﬁc infant mortality, has no inﬂu-
ence on any of the other causes of death in their infants
and is not an effective strategy to improve neonatal or
infant survival. It also appears that vitamin A supple-
mentation in women of reproductive age has no role in
reducing overall or cause-speciﬁc infant mortality in
child survival programs. We also failed to demonstrate
any harm from vitamin A supplementation in infant
males or females in our study population. These ﬁndings
add to the ongoing debate about the safety of vitamin A
supplementation and whether vitamin A supplementa-
tion may have differential effects on mortality in boys
and girls in early and late infancy.
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